• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续病毒学应答患者的进行性肝纤维化与肝细胞癌显著相关。

Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response.

机构信息

Department of Gastroenterology, Komaki City Hospital, Komaki, Japan.

出版信息

Hepatol Res. 2015 Jan;45(2):238-46. doi: 10.1111/hepr.12331. Epub 2014 Apr 24.

DOI:10.1111/hepr.12331
PMID:24655233
Abstract

AIM

Hepatocellular carcinoma develops even in some patients who achieve a sustained virological response following treatment for hepatitis C virus infection. This study investigated the relationship between changes in fibrosis, as assessed by sequential biopsies, and development of hepatocellular carcinoma in patients who achieved a sustained virological response for hepatitis C virus.

METHODS

We enrolled 97 patients with sustained virological response who had undergone initial biopsies before therapy and sequential biopsies at an average of 5.8 ± 1.9 years after the initial biopsy. Factors associated with hepatocellular carcinoma were retrospectively analyzed.

RESULTS

The liver fibrotic stage regressed in 44 patients (45%), remained stable in 47 patients (48%) and progressed in six patients (6%). The fibrotic stage significantly decreased, from 1.54 ± 0.86 to 1.16 ± 1.07 units. Hepatocellular carcinoma was identified in 12 patients (12.4%). The cumulative incidence of hepatocellular carcinoma in patients with progressive fibrosis was significantly higher than that in patients with regressed or stable fibrosis (P < 0.001). A Cox proportional hazards regression analysis confirmed that progressive fibrosis in sequential liver biopsies (hazard ratio [HR], 8.30; P = 0.001) and low platelet counts before treatment (HR, 8.69; P = 0.006) were significant independent factors associated with the development of hepatocellular carcinoma in patients with a sustained virological response.

CONCLUSION

Progressive fibrosis, assessed by sequential biopsies, was significantly correlated with development of hepatocellular carcinoma in patients who had achieved a sustained virological response for hepatitis C virus.

摘要

目的

即使在丙型肝炎病毒感染治疗后获得持续病毒学应答的患者中,也会发生肝细胞癌。本研究调查了通过连续肝活检评估的纤维化变化与丙型肝炎病毒持续病毒学应答患者发生肝细胞癌之间的关系。

方法

我们纳入了 97 例获得持续病毒学应答的患者,这些患者在治疗前进行了初次肝活检,并在初次肝活检后平均 5.8±1.9 年进行了连续肝活检。回顾性分析了与肝细胞癌相关的因素。

结果

44 例患者(45%)的肝纤维化分期消退,47 例患者(48%)稳定,6 例患者(6%)进展。纤维化分期显著降低,从 1.54±0.86 降至 1.16±1.07 单位。12 例患者(12.4%)确诊为肝细胞癌。进展性纤维化患者的肝细胞癌累积发生率明显高于纤维化消退或稳定患者(P<0.001)。Cox 比例风险回归分析证实,连续肝活检中的进展性纤维化(风险比[HR],8.30;P=0.001)和治疗前血小板计数低(HR,8.69;P=0.006)是与持续病毒学应答患者肝细胞癌发展相关的显著独立因素。

结论

通过连续肝活检评估的进展性纤维化与丙型肝炎病毒持续病毒学应答患者肝细胞癌的发生显著相关。

相似文献

1
Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response.持续病毒学应答患者的进行性肝纤维化与肝细胞癌显著相关。
Hepatol Res. 2015 Jan;45(2):238-46. doi: 10.1111/hepr.12331. Epub 2014 Apr 24.
2
α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.干扰素治疗后甲胎蛋白水平可预测病毒学持续应答患者肝纤维化的消退情况。
J Gastroenterol Hepatol. 2016 May;31(5):1001-8. doi: 10.1111/jgh.13245.
3
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression.慢性丙型肝炎患者经干扰素治疗后实现病毒应答且肝硬化得到缓解,其肝细胞癌风险持续存在。
Liver Int. 2018 Aug;38(8):1459-1467. doi: 10.1111/liv.13707. Epub 2018 Mar 12.
4
Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.接受直接抗病毒治疗并获得持续病毒学应答的丙型肝炎病毒感染患者中,肝脏硬度和脂肪变性与肝细胞癌发生的关联
Hepatol Res. 2021 Aug;51(8):860-869. doi: 10.1111/hepr.13677. Epub 2021 Jun 7.
5
Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.丙型肝炎病毒感染患者在接受干扰素治疗后获得持续病毒学应答后发生肝细胞癌的情况:一项大规模、长期队列研究。
J Gastroenterol Hepatol. 2016 May;31(5):1009-15. doi: 10.1111/jgh.13236.
6
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.接受 DAA 治疗的晚期丙型肝炎患者新诊断的肝细胞癌:一项前瞻性人群研究。
J Hepatol. 2018 Aug;69(2):345-352. doi: 10.1016/j.jhep.2018.03.009. Epub 2018 Mar 16.
7
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.干扰素治疗可降低肝细胞癌风险:日本慢性丙型肝炎肝硬化和非肝硬化患者的全国监测项目。IHIT研究组。干扰素治疗对肝癌发生的抑制作用。
Ann Intern Med. 1999 Aug 3;131(3):174-81. doi: 10.7326/0003-4819-131-3-199908030-00003.
8
Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals.治疗后纤维化改变超过治疗前肝纤维化,可预测 CHC 患者接受根治性抗病毒治疗后的 HCC。
Hepatol Int. 2018 Nov;12(6):544-551. doi: 10.1007/s12072-018-9908-4. Epub 2018 Nov 13.
9
Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.加拿大丙型肝炎患者持续病毒学应答对肝细胞癌的长期影响。
J Hepatol. 2017 Mar;66(3):504-513. doi: 10.1016/j.jhep.2016.10.028. Epub 2016 Nov 4.
10
Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.通过天冬氨酸氨基转移酶与血小板比值指数预测慢性丙型肝炎患者持续病毒学应答后肝细胞癌的风险
Gut Liver. 2016 Sep 15;10(5):796-802. doi: 10.5009/gnl15368.

引用本文的文献

1
Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.治疗前血清血管生成素-2可预测丙型肝炎病毒相关失代偿性肝硬化患者使用索磷布韦和维帕他韦成功根除丙型肝炎病毒后的预后及肝功能储备。
J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02275-3.
2
Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals.丙型肝炎患者使用直接抗病毒药物治疗获得5年持续病毒学应答后纤维化的组织学改善情况。
J Gastroenterol. 2025 Feb;60(2):197-209. doi: 10.1007/s00535-024-02165-0. Epub 2024 Nov 25.
3
Clinical factors to predict changes of esophagogastric varices after sustained viral response with direct-acting antiviral therapy.
预测直接抗病毒治疗实现持续病毒学应答后食管胃静脉曲张变化的临床因素。
J Gastroenterol. 2025 Feb;60(2):222-234. doi: 10.1007/s00535-024-02174-z. Epub 2024 Nov 15.
4
Progression of chronic liver disease to hepatocellular carcinoma: implications for surveillance and management.慢性肝病进展为肝细胞癌:对监测和管理的意义
BJC Rep. 2024 May 3;2(1):39. doi: 10.1038/s44276-024-00050-0.
5
Association between Liver Stiffness and Liver-Related Events in HCV-Infected Patients after Successful Treatment with Direct-Acting Antivirals.直接作用抗病毒药物治疗后 HCV 感染患者肝硬度与肝脏相关事件的相关性。
Medicina (Kaunas). 2023 Mar 18;59(3):602. doi: 10.3390/medicina59030602.
6
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.血清血管生成素 2 预测丙型肝炎直接抗病毒治疗后肝细胞癌的发生和复发。
Viruses. 2023 Jan 7;15(1):181. doi: 10.3390/v15010181.
7
Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia.血小板减少症对 HCV 相关肝硬化患者持续病毒学应答后肝功能和临床结局的低成本预测因子。
Medicina (Kaunas). 2023 Jan 11;59(1):146. doi: 10.3390/medicina59010146.
8
Longitudinal increase in albumin-bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis.白蛋白-胆红素评分的纵向升高与肝硬化患者的非恶性相关死亡率和生活质量相关。
PLoS One. 2022 Feb 3;17(2):e0263464. doi: 10.1371/journal.pone.0263464. eCollection 2022.
9
Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response.载脂蛋白 PNPLA3 在慢性丙型肝炎病毒感染者获得持续病毒学应答后评估和监测肝脂肪变性和纤维化中的作用。
Medicina (Kaunas). 2021 Oct 24;57(11):1153. doi: 10.3390/medicina57111153.
10
BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial.BMS-986263 治疗晚期肝纤维化患者的 36 周结果:一项随机、安慰剂对照的 2 期临床试验。
Hepatology. 2022 Apr;75(4):912-923. doi: 10.1002/hep.32181. Epub 2021 Dec 13.